CRIS Current Research Information System

PALANDRI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.516
AS - Asia 7.870
EU - Europa 5.738
Continente sconosciuto - Info sul continente non disponibili 494
SA - Sud America 480
AF - Africa 470
OC - Oceania 15
Totale 24.583
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.316
SG - Singapore 2.104
VN - Vietnam 2.048
CN - Cina 1.974
GB - Regno Unito 1.331
IT - Italia 999
SE - Svezia 844
DE - Germania 717
HK - Hong Kong 462
IN - India 401
FR - Francia 376
BR - Brasile 351
RU - Federazione Russa 302
NL - Olanda 226
IE - Irlanda 218
JP - Giappone 202
UA - Ucraina 163
FI - Finlandia 138
KR - Corea 138
ZA - Sudafrica 133
BD - Bangladesh 128
CI - Costa d'Avorio 120
CA - Canada 119
EE - Estonia 103
TG - Togo 98
JO - Giordania 63
CH - Svizzera 58
BG - Bulgaria 54
PH - Filippine 51
TR - Turchia 49
BE - Belgio 47
AR - Argentina 42
PL - Polonia 39
TH - Thailandia 39
NG - Nigeria 36
ID - Indonesia 35
TW - Taiwan 34
MX - Messico 32
AT - Austria 25
EC - Ecuador 25
IQ - Iraq 25
IR - Iran 24
ES - Italia 21
SC - Seychelles 20
CL - Cile 16
PK - Pakistan 16
CZ - Repubblica Ceca 14
SA - Arabia Saudita 14
AU - Australia 12
JM - Giamaica 12
VE - Venezuela 12
MA - Marocco 11
AE - Emirati Arabi Uniti 10
CO - Colombia 10
ET - Etiopia 10
GR - Grecia 10
LB - Libano 10
LT - Lituania 10
PY - Paraguay 10
GT - Guatemala 9
RO - Romania 9
CR - Costa Rica 8
EG - Egitto 8
KE - Kenya 8
UZ - Uzbekistan 8
DZ - Algeria 7
PE - Perù 7
DK - Danimarca 6
IL - Israele 6
LV - Lettonia 6
MY - Malesia 6
TN - Tunisia 6
LY - Libia 5
AL - Albania 4
NI - Nicaragua 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
BO - Bolivia 3
HR - Croazia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
CY - Cipro 2
GH - Ghana 2
HN - Honduras 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
Totale 24.074
Salva come PNG Salva come JPEG
Città #
Singapore 1.460
Southend 1.166
Ashburn 1.003
Fairfield 820
Chandler 741
San Jose 613
Hong Kong 441
Dong Ket 414
Seattle 402
Ho Chi Minh City 392
Hanoi 391
Houston 391
Wilmington 374
Woodbridge 372
Beijing 322
Cambridge 307
Princeton 279
Santa Clara 265
Ann Arbor 247
Hefei 239
Dublin 218
Bologna 196
Boardman 176
Tokyo 168
Council Bluffs 164
Dallas 160
Los Angeles 144
Lauterbourg 141
New York 131
Nanjing 128
Abidjan 120
Helsinki 115
Westminster 115
Seoul 113
Lomé 98
Padova 97
Milan 90
Jacksonville 80
Jinan 74
Buffalo 71
Berlin 68
Munich 65
Amman 62
Shenyang 61
Turin 61
Bremen 60
Saint Petersburg 56
Haiphong 53
Sofia 53
São Paulo 52
Da Nang 51
Frankfurt am Main 49
Chicago 47
Brussels 46
Redondo Beach 46
Bern 45
Hyderabad 44
San Diego 44
Falls Church 42
Rome 39
Shanghai 39
Redmond 38
Changsha 37
Guangzhou 36
Abeokuta 33
Nanchang 33
Cornaredo 32
Falkenstein 32
Orem 30
Warsaw 30
Medford 29
Toronto 29
Zhengzhou 29
Hangzhou 28
Montreal 28
Phoenix 28
Jiaxing 26
Johannesburg 26
London 26
Bengaluru 25
Nuremberg 25
Tianjin 25
Des Moines 24
Florence 24
Hebei 24
North Bergen 23
Biên Hòa 22
Redwood City 22
Chengdu 21
Brooklyn 20
Can Tho 20
Clifton 20
Dearborn 20
Jakarta 20
Norwalk 20
Boston 19
San Francisco 19
Haikou 18
Manaus 18
Piscataway 18
Totale 15.318
Salva come PNG Salva come JPEG
Nome #
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 318
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 306
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 284
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 279
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 265
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 257
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 253
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 249
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 240
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 233
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 232
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 231
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 229
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 219
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 218
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 217
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 214
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 211
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 210
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 209
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 208
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 208
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 205
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 202
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 199
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 197
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 195
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 194
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 193
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 193
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 193
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 192
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 190
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 188
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 187
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 187
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 186
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 185
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 183
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 182
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 182
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 181
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 180
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 180
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 178
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
The “vesicular intelligence” strategy of blood cancers 173
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 171
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 171
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 171
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 169
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 169
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 167
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 166
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 166
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 166
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 165
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 164
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 163
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 163
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 161
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 160
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 160
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 159
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 157
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 156
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 156
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 155
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 152
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 150
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 150
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 149
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 147
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 146
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance 145
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 143
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 143
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 143
Diagnosis and classification of the risk 143
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 143
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 143
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 143
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 143
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 142
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 142
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 142
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 140
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 140
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 139
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 137
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 136
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 136
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 134
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 134
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 133
Hollow fiber flow field-flow fractionation enables high-quality Extracellular Vesicle isolation from minimal plasma samples in polycythemia vera liquid biopsy 131
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 131
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 131
Totale 18.030
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.203
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.203
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.424 0 66 147 281 219 144 56 192 96 268 501 454
2022/20232.919 338 441 176 391 194 243 88 167 477 93 195 116
2023/2024909 57 135 55 87 63 186 56 61 33 67 56 53
2024/20253.256 163 421 260 279 367 166 233 132 86 298 137 714
2025/20267.737 579 610 718 509 824 420 700 456 1.654 628 301 338
2026/2027790 405 385 0 0 0 0 0 0 0 0 0 0
Totale 24.583